Robin Glover, PT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 571 Court Street, Stes A-c Professional Building, Appomattox, VA 24522 Phone: 434-845-9053 |
Jason Gulstrom, PT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 571 Court Street, Appomattox, VA 24522 Phone: 434-352-5799 Fax: 434-509-1695 |
Jordan Molstre Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 571 Court Street, Appomattox, VA 24522 Phone: 434-845-9053 |
Mrs. Candice N Gilbert, MPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 667 Police Tower Rd, Appomattox, VA 24522 Phone: 434-229-2700 |
Brenda Murphy, PT, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 571 Court Street, A-c Prof Bldg, Appomattox, VA 24522 Phone: 434-352-5799 Fax: 434-509-1695 |
Allison Brooke Barksdale, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 571 Court Street, Appomattox, VA 24522 Phone: 434-352-5799 Fax: 434-352-9559 |
News Archive
When faced with disease, patients and caregivers now readily turn to the Internet for information and emotional support. This is particularly true in the case of caregivers of children with hydrocephalus.
The Ensign Group, Inc. (Nasdaq: ENSG), announced today that it has acquired three Utah skilled nursing facilities, South Valley Care Center in West Jordan, a suburb of Salt Lake City, Rock Canyon Rehab & Care Center in Provo, and Castle Country Care Center in Price.
In older breast cancer survivors, the number of lymph nodes removed during surgery and the presence of cancer in the lymph nodes were the two factors most directly linked to the development of lymphedema, swelling of the arm and hand, according to a study from the Medical College of Wisconsin's Center for Patient Care and Outcomes Research in Milwaukee, Wisconsin.
They say that a picture can be worth a thousand words. This especially is true for describing the structures of molecules that function to promote cancer.
YM BioSciences Inc., announced the conclusion of dose-escalation in the Phase I portion of its Phase I/II clinical trial of CYT387 at Mayo Clinic in patients with myelofibrosis. In total, 21 patients were treated in Phase I, with no voluntary withdrawals reported. CYT387 has shown significant activity in reducing spleen size and controlling constitutional symptoms in these patients.
› Verified 7 days ago